Advertisement
Screener

Oncotelic Therapeutics, Inc. (OTLC) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.9 / 5 stars · 15/40 Roast Me

Oncotelic Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-15.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2022-04-15

  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-03-31 was 0.00%.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-03-31 was 0.00%.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2015-03-31 was 0.00%.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-03-31 was 0.00%.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.00%.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2021-12-310.00%
10-K · filed 2022-04-15
2021-06-300.00%
10-Q · filed 2021-08-20
2018-12-310.00%
10-K · filed 2019-04-10
2018-09-300.00%
10-Q · filed 2018-11-14
2018-06-300.00%
10-Q · filed 2018-08-14
2017-12-310.00%
10-K · filed 2019-04-10
2017-09-300.00%
10-Q · filed 2018-11-14
2017-06-300.00%
10-Q · filed 2018-08-14
2017-03-310.00%
10-Q · filed 2018-05-14
2016-12-310.00%
10-K · filed 2018-04-17
2016-09-300.00%
10-Q · filed 2017-11-14
2016-06-300.00%
10-Q · filed 2017-08-02
2016-03-310.00%
10-Q · filed 2017-05-08
2015-12-310.00%
10-K · filed 2017-03-30
2015-09-300.00%
10-Q · filed 2016-11-14
2015-06-300.00%
10-Q · filed 2016-08-02
2015-03-310.00%
10-Q · filed 2016-05-06
2014-12-310.00%
10-K · filed 2016-03-25
2014-09-300.00%
10-Q · filed 2015-11-12
2014-06-300.00%
10-Q · filed 2015-08-06
2014-03-310.00%
10-Q · filed 2014-05-08
2013-12-310.00%
10-K · filed 2015-03-30
2013-09-300.00%
10-Q · filed 2013-11-13
2013-06-300.00%
10-Q/A · filed 2013-10-18
2013-03-310.00%
10-Q · filed 2013-05-09
2012-12-310.00%
10-K · filed 2015-03-30
2012-09-300.00%
10-Q · filed 2012-11-09
2012-06-300.00%
10-Q · filed 2012-08-13
2011-12-310.00%
10-K · filed 2014-03-20
2010-12-310.00%
10-K · filed 2013-03-15